Volume 49, Issue 5, Pages (May 2006)

Slides:



Advertisements
Similar presentations
Volume 45, Issue 5, Pages (May 2004)
Advertisements

A Double-Blind Placebo-Controlled Randomized Clinical Trial With Magnesium Oxide to Reduce Intrafraction Prostate Motion for Prostate Cancer Radiotherapy 
The PSA Era is not Over for Prostate Cancer
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Testosterone Therapy in Men With Prostate Cancer
Volume 56, Issue 6, Pages (December 2009)
Volume 53, Issue 4, Pages (April 2008)
Volume 54, Issue 6, Pages (December 2008)
Volume 66, Issue 4, Pages (October 2014)
Validity and Reliability of a Questionnaire for Evaluating Nocturia, Nocturnal Enuresis and Sleep-Interruptions in an Elderly Population  M.H. Bing, L.A.
Volume 53, Issue 5, Pages (May 2008)
Volume 69, Issue 1, Pages (January 2016)
Volume 51, Issue 4, Pages (April 2007)
Volume 66, Issue 6, Pages (December 2014)
Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?
Prostate Cancer Epidemic in Sight?
Volume 70, Issue 5, Pages (November 2016)
Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer  Olav Erich Yri, Trine Bjoro, Sophie D.
John P. Mulhall, Francesco Montorsi  European Urology 
Tumour Grade, Treatment, and Relative Survival in a Population-based Cohort of Men with Potentially Curable Prostate Cancer  Sam Ladjevardi, Gabriel Sandblom,
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Volume 74, Issue 4, Pages (October 2018)
Volume 60, Issue 4, Pages (October 2011)
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes  European Urology 
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Volume 47, Issue 5, Pages (May 2005)
Volume 63, Issue 4, Pages (April 2013)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Yuanshan Cui, Yong Zhang  European Urology 
Volume 65, Issue 2, Pages (February 2014)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 53, Issue 4, Pages (April 2008)
Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward?  Michel Bolla  European.
Volume 63, Issue 3, Pages (March 2013)
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Volume 65, Issue 6, Pages (June 2014)
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements 
Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care  Fred Saad, Carl Olsson, Claude C. Schulman 
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 48, Issue 6, Pages (December 2005)
Volume 50, Issue 5, Pages (November 2006)
Volume 46, Issue 5, Pages (November 2004)
Ben Colagiuri, PhD, Haryana Dhillon, PhD, Phyllis N
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Evaluating Cognitive, Emotional, and Physical Fatigue Domains in Daily Practice by Single-Item Questions in Patients With Advanced Cancer: A Cross-Sectional.
Oral pentasa in the treatment of active Crohn’s disease: A meta-analysis of double- blind, placebo-controlled trials  Stephen B Hanauer, Ulf Strömberg 
Volume 74, Issue 5, Pages (November 2018)
Jacques Irani  European Urology Supplements 
Volume 49, Issue 4, Pages (April 2006)
Community-acquired pneumonia: the evolving challenge
Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer  Amar U. Kishan, Rahul.
Volume 72, Issue 2, Pages (August 2017)
Long-Term Hormonal Therapy: Who Would Benefit?
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?  O.A. Cornely  Clinical Microbiology and.
Volume 53, Issue 6, Pages (June 2008)
European Urology is “Your” Journal
A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study  John Fitzpatrick  European.
Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.
Role of Transurethral Resection of the Prostate and Biopsy of the Peripheral Zone in the Same Session after Repeated Negative Biopsies in the Diagnosis.
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Improving Flexibility and Quality of Life for Your Patients: A Must?
Manfred Wirth, Peter Iversen, David McLeod, William See 
Bertrand Tombal, Richard Berges
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 51, Issue 5, Pages (May 2007)
Presentation transcript:

Volume 49, Issue 5, Pages 781-789 (May 2006) Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasentan Influence Quality of Life?  David Cella, Daniel P. Petrylak, Mayer Fishman, Chris Teigland, Jay Young, Parvez Mulani  European Urology  Volume 49, Issue 5, Pages 781-789 (May 2006) DOI: 10.1016/j.eururo.2005.12.058 Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 1 Time to disease progression in atrasentan trials: Data are shown from the meta-analysis (studies M00-211 and M96-594) intent-to-treat population and from the intent-to-treat and evaluable populations in a phase II trial (study M96-594) and a phase III trial (study M00-211). Data are presented as hazard ratio with 95% confidence intervals. ITT=intent-to-treat. European Urology 2006 49, 781-789DOI: (10.1016/j.eururo.2005.12.058) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 2 Mean QOL treatment difference between patients in the placebo group and 10mg atrasentan group using analysis of covariance. Data are shown from the meta-analysis as mean difference with 95% confidence intervals. QOL=Quality of Life. European Urology 2006 49, 781-789DOI: (10.1016/j.eururo.2005.12.058) Copyright © 2006 Elsevier B.V. Terms and Conditions

Fig. 3 Quality-adjusted time to disease progression for FACT-P and EORTC QLQ C-30 domains. In this phase III trial, patients were randomized to once-daily atrasentan 10mg or placebo and treated until disease progression. Data are presented as hazard ratio with 95% confidence intervals. FACT-P=Functional Assessment of Cancer Therapy-Prostate; PCS=Prostate Cancer Subscore; EORTC=European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). European Urology 2006 49, 781-789DOI: (10.1016/j.eururo.2005.12.058) Copyright © 2006 Elsevier B.V. Terms and Conditions